Madrigal Pharmaceuticals Inc

+0.15 (+0.22%)
Earnings Announcements

Madrigal Pharmaceuticals Reports First Quarter Financial Results

Published: 05/09/2022 13:45 GMT
Madrigal Pharmaceuticals Inc (MDGL) - Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results.
As of March 31, 2022, Madrigal Had Cash, Cash Equivalents and Marketable Securities of $220.0 Million.
Qtrly Basic and Diluted Net Loss per Common Share$3.36.
Q1 Earnings per Share View $-3.62 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$3.70

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$3.75

More details on our Analysts Page.